ACCRETION PHARMA LIMITED Stock Price Today (NSE: ACCPL)
Fundamental Score
ACCRETION PHARMA LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ACCRETION PHARMA LIMITED share price today is ₹210.85, up +0.98% on NSE/BSE as of 17 September 2026. ACCRETION PHARMA LIMITED (ACCPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹178.58 (Cr). The 52-week high for ACCPL share price is ₹219.00 and the 52-week low is ₹53.80. At a P/E ratio of 18.47x, ACCPL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 27.63% and a debt-to-equity ratio of 0.23.
ACCRETION PHARMA LIMITED Share Price Chart — NSE/BSE Historical Performance
ACCRETION PHARMA LIMITED share price chart: 6.29% return over the past month. 52-week high ₹219.00, 52-week low ₹53.80.
ACCRETION PHARMA LIMITED — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹208.80 | ₹214.00 | ₹208.00 | ₹210.85 | 38.40K (Cr) | |
| ₹209.00 | ₹211.00 | ₹208.05 | ₹208.80 | 19.20K (Cr) | |
| ₹215.00 | ₹219.00 | ₹210.00 | ₹219.00 | 8.40K (Cr) | |
| ₹207.60 | ₹215.00 | ₹207.55 | ₹215.00 | 13.20K (Cr) | |
| ₹201.55 | ₹210.00 | ₹201.55 | ₹210.00 | 6.00K (Cr) | |
| ₹205.00 | ₹210.00 | ₹201.00 | ₹202.00 | 8.40K (Cr) | |
| ₹210.00 | ₹210.00 | ₹210.00 | ₹210.00 | 1.20K (Cr) | |
| ₹201.90 | ₹210.00 | ₹201.90 | ₹210.00 | 68.40K (Cr) | |
| ₹202.00 | ₹202.00 | ₹200.00 | ₹200.00 | 13.20K (Cr) | |
| ₹210.00 | ₹210.00 | ₹202.00 | ₹202.00 | 7.20K (Cr) |
ACCRETION PHARMA LIMITED — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹207.00 | ₹219.00 | ₹200.00 | ₹210.85 | +1.86% | |
| ₹171.00 | ₹214.70 | ₹165.45 | ₹207.00 | +21.05% | |
| ₹165.25 | ₹171.80 | ₹155.60 | ₹169.90 | +2.81% | |
| ₹129.00 | ₹133.85 | ₹127.00 | ₹133.65 | +3.60% | |
| ₹114.05 | ₹127.00 | ₹107.00 | ₹117.45 | +2.98% | |
| ₹69.70 | ₹103.50 | ₹65.70 | ₹103.50 | +48.49% | |
| ₹63.00 | ₹68.00 | ₹62.00 | ₹63.55 | +0.87% | |
| ₹66.05 | ₹73.20 | ₹66.05 | ₹68.50 | +3.71% | |
| ₹84.00 | ₹86.70 | ₹67.00 | ₹67.40 | -19.76% | |
| ₹88.10 | ₹102.00 | ₹83.70 | ₹88.00 | -0.11% | |
| ₹58.25 | ₹84.50 | ₹55.15 | ₹81.15 | +39.31% | |
| ₹58.25 | ₹58.95 | ₹53.80 | ₹56.75 | -2.58% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ACCRETION PHARMA LIMITED Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACCRETION PHARMA LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACCPL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (27.63%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.89%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 18.47 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (18.24%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (16.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.52%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
ACCRETION PHARMA LIMITED vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ACCRETION PHARMA LIMITED with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
42.9/100 | ₹210.85₹211 | ₹178.58₹178.58 | 18.47Average 18.5 Average | 27.63%Excellent 27.63% Excellent | 28.89%Excellent 28.89% Excellent | 0.23Excellent 0.2 Excellent | — — | — — | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
ACCRETION PHARMA LIMITED Quarterly Performance
Latest quarterly metrics for ACCPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
18.24%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
13.63%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
ACCRETION PHARMA LIMITED Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ACCPL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
ACCRETION PHARMA LIMITED Financial Statements
Annual income statement, balance sheet and cash flow for ACCRETION PHARMA LIMITED (ACCPL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for ACCRETION PHARMA LIMITED
About ACCPL (ACCRETION PHARMA LIMITED)
ACCRETION PHARMA LIMITED (ACCPL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a ...current market capitalisation of ₹178.58 (Cr). ACCRETION PHARMA LIMITED has delivered a Return on Equity (ROE) of 27.63% and a ROCE of 28.89%. The debt-to-equity ratio stands at 0.23, reflecting the company's capital structure. Investors tracking ACCPL share price can monitor key metrics including P/E ratio, promoter holding of 73.52%, and quarterly earnings growth.
Company Details
ACCPL Share Price: Frequently Asked Questions
What is the current share price of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED (ACCPL) trades at ₹210.85 on NSE. Market cap ₹178.58 (Cr). Educational data only.
What is the P/E ratio of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has a P/E of 18.47x vs industry average 34.89x.
What is the Bull Run score for ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has a Bull Run score of 42.9/100 based on 25+ financial parameters.
Does ACCRETION PHARMA LIMITED pay dividends?
ACCRETION PHARMA LIMITED has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has ROE of 27.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has debt-to-equity of 0.23.
Is ACCRETION PHARMA LIMITED a good investment?
Bull Run gives ACCRETION PHARMA LIMITED a score of 42.9/100. This is not investment advice — consult a SEBI-registered advisor.